Goldman Sachs Group Inc. Boosts Position in Keros Therapeutics, Inc. $KROS

Goldman Sachs Group Inc. increased its holdings in shares of Keros Therapeutics, Inc. (NASDAQ:KROS) by 38.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 740,606 shares of the company’s stock after purchasing an additional 205,022 shares during the quarter. Goldman Sachs Group Inc. owned approximately 1.82% of Keros Therapeutics worth $7,547,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. GAMMA Investing LLC lifted its stake in Keros Therapeutics by 7,690.3% in the first quarter. GAMMA Investing LLC now owns 2,415 shares of the company’s stock valued at $237,000 after buying an additional 2,384 shares during the last quarter. FNY Investment Advisers LLC purchased a new stake in Keros Therapeutics in the first quarter valued at approximately $25,000. CWM LLC lifted its stake in Keros Therapeutics by 10,157.7% in the first quarter. CWM LLC now owns 2,667 shares of the company’s stock valued at $27,000 after buying an additional 2,641 shares during the last quarter. ProShare Advisors LLC lifted its stake in Keros Therapeutics by 35.5% in the fourth quarter. ProShare Advisors LLC now owns 10,549 shares of the company’s stock valued at $167,000 after buying an additional 2,764 shares during the last quarter. Finally, Entropy Technologies LP purchased a new stake in Keros Therapeutics in the first quarter valued at approximately $121,000. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on KROS. Wedbush reiterated a “neutral” rating and issued a $15.00 price objective on shares of Keros Therapeutics in a research note on Friday, May 30th. Bank of America cut Keros Therapeutics from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $32.00 to $18.00 in a research note on Tuesday, June 10th. Finally, HC Wainwright dropped their target price on Keros Therapeutics from $25.00 to $20.00 and set a “buy” rating on the stock in a report on Friday, August 8th. Seven investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $30.00.

Keros Therapeutics Price Performance

Shares of KROS stock opened at $15.66 on Friday. The business’s fifty day moving average price is $14.62 and its 200 day moving average price is $13.50. Keros Therapeutics, Inc. has a 1-year low of $9.12 and a 1-year high of $72.37. The firm has a market capitalization of $636.03 million, a PE ratio of 50.52, a P/E/G ratio of 2.03 and a beta of 1.06.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.76) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.14) by $0.38. Keros Therapeutics had a return on equity of 2.96% and a net margin of 8.06%.The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $3.83 million. During the same quarter in the prior year, the company posted ($1.25) earnings per share. Keros Therapeutics’s quarterly revenue was up 49002.7% on a year-over-year basis. Equities research analysts expect that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current fiscal year.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.